Dr. Kadia on E-selectin as a Target in the Treatment of AML

Supplements And Featured PublicationsMilestones in Medicine: Updates in AML
Volume 1
Issue 1

Tapan M. Kadia, MD, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia.

Tapan M. Kadia, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia (AML).

E-selectin is a marker that is present in the tumor microenvironment for patients with AML, Kadia says. E-selectin serves as a marker that binds to leukemia cells, protecting them by activating cell survival and growth pathways and promoting resistance to chemotherapy in AML, Kadia explains.

By disrupting the interaction of E-selectin and leukemia cells in the tumor microenvironment, AML cells can become more sensitive to chemotherapy, Kadia notes. Uproleselan, a novel E-selectin antagonist, is designed to bind to E-selectin to make AML cells more vulnerable to systemic treatments, potentially leading to better outcomes, response rates, and long-term survival for patients with AML, Kadia concludes.

Related Videos
Timothy I Shaw, PhD
Mohamad Mohty, MD, PhD
Haifa Kathrin Al-Ali, MD
Ann H. Partridge, MD, MPH
Brian A. Van Tine, MD, PhD
Shubham Pant, MD, MBBS
Benjamin L. Schlechter, MD
Harry Gill, MD, FRCP, FRCPath
Elias Jabbour, MD
Bernd Kasper, MD, PhD
Related Content